Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observer-blinded, Randomized, Controlled, Phase 2 Study to Evaluate the Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac COVID-19 Vaccines or One Formulation of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) Determined in a lead-in Formulation Finding in Healthy Adults.

Next Previous
X
Search
Trial Profile

An Observer-blinded, Randomized, Controlled, Phase 2 Study to Evaluate the Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac COVID-19 Vaccines or One Formulation of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) Determined in a lead-in Formulation Finding in Healthy Adults.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 1222 (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; SCB 2019 (Primary)
  • Indications COVID 2019 infections
  • Focus Pharmacodynamics

    • Most Recent Events

    • 05 Jun 2022 According to a Clover Biopharmaceuticals media release, since the CoronaVac booster study group had met significant challenges with enrollment due to a preference for other licensed vaccines, the investigators and study funders have decided to terminate the study.
    • 05 Jun 2022 Status changed from recruiting to discontinued, acording to a Clover Biopharmaceuticals media release.
    • 14 Feb 2022 According to a Clover Biopharmaceuticals media release, initial data from SCB-2019 (CpG 1018/Alum) as a booster in individuals who previously received two doses of Coronavac is expected by Q2-2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top